Raymond James reiterates Outperform on Regeneron stock at $910 target By Investing.com

Raymond James reiterated an Outperform rating on Regeneron and kept its $910 price target after the company’s C5 complement program investor event, citing progress in generalized myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy. The firm added gMG to its model and estimates U.S. revenue of $91 million in 2027, rising to $512 million by 2030. Additional support came from detailed Phase 3 NIMBLE trial publication and multiple other analyst price-target updates, including Piper Sandler at $875 and Bernstein at $921.

Analysis

REGN’s setup is less about one data readout and more about optionality stacking across three catalysts with very different win conditions. The market is already paying for durable base franchise cash flows, so the real upside comes from the re-rating that can occur if the C5 platform looks like a multi-indication standard rather than a single-asset story; that would also improve the market’s willingness to capitalize the pipeline at a higher multiple instead of treating it as a discount to earnings.

The second-order winner, if efficacy and dosing convenience hold up, is not just REGN but the broader “platform validation” trade in complement inhibition. A cleaner profile versus existing complement therapies would pressure adjacent programs in rare disease and force competitors to compete on durability and administration burden, not just efficacy. In PNH and geographic atrophy, the bigger commercial question is not peak share alone but whether payers will reimburse a potentially premium-priced regimen if it can reduce infusion burden and total-care costs.

The main risk is timing mismatch: the stock can continue to grind higher into late-2026 catalyst season, but a single trial miss could compress the pipeline premium quickly because the current debate is concentrated in a narrow set of readouts. The market also appears to be underestimating execution risk on label breadth and differentiation; even a positive gMG outcome may not translate to broad rerating if the commercial model implies slower uptake than bulls expect. For TLX, the collaboration is strategically positive but remains a capital-allocation story unless it proves REGN is willing to buy capability rather than just science.

Contrarianly, the move may be less about upside surprise and more about reducing perceived binary risk. If that’s right, implied volatility into the 4Q26 window is likely to rise before fundamentals fully improve, creating a better entry in options than in outright stock. The crowded long-biotech ownership base means the path of least resistance is a patient hold with catalyst hedges, not aggressive chase buying after a six-month rally.

Key Decisions for Investors

• Maintain a core long REGN, but trim 20-30% into strength ahead of 4Q26 and re-add on pullbacks; the stock is likely to trade on catalyst probability rather than near-term fundamentals, so avoid full-size chase risk.
• Buy REGN Jan-2027 call spreads financed partially by selling lower-strike calls; the setup is attractive for a delayed catalyst stack where upside is driven by multiple shots on goal, but the premium should be capped to reflect readout risk.
• Pair trade: long REGN / short a basket of single-asset rare-disease peers with less diversified earnings power; if C5 platform validation holds, REGN should earn a higher quality multiple versus narrower pipeline names over the next 6-12 months.
• For event-driven accounts, buy volatility into the late-2026 catalyst window only on pullbacks; the key risk-reward is asymmetric if implied vol lags the true probability of a pivotal miss or label disappointment.
• Treat TLX as a non-core watchlist long only on evidence of expanding strategic investment; until then, it is better viewed as a capability signal than a standalone earnings driver.